Jose Carmona

Pepe has served as Chief Financial Officer of Rubius Therapeutics since September 2020, where he is responsible for all financial aspects of the business, investor relations, business development and information technology.

Rubius Therapeutics, Inc. (Nasdaq: RUBY) is a clinical-stage biophar­ma­ceu­tical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases.

Pepe previously served as the Chief Financial Officer of Radius Health, a biophar­ma­ceu­tical company developing and commercializing endocrine therapeutics. Under Pepe’s leadership, Radius Health was transformed from a clinical-stage company to a fully commercial organization. Pepe was instrumental in financing the company’s commer­cial­iza­tion and pipeline investments, executing several business development transactions and building the finance organization, processes and systems. Prior to joining Radius, Pepe was Chief Financial Officer of Innocoll Holdings PLC, acquired by Gurnet Point L.P. Previously, Pepe held numerous financial management positions with increasing responsibilities at Novartis AG across various divisions, including chief financial officer roles in Europe, North America and Latin America, among other senior global financial roles.

Pepe received his B.S. in Industrial Civil Engineering from Universidad Tecnica Federico Santa Maria in Valparaiso, Chile, and his M.B.A. from Columbia Business School in New York City.